singlestrand
rna
virus
posit
neg
polar
use
vector
vaccin
develop
context
alphavirus
flavivirus
measl
viru
rhabdovirus
engin
express
surfac
protein
gene
antigen
administr
replicon
rna
vector
result
strong
immun
respons
gener
neutral
antibodi
variou
anim
model
immun
mice
chicken
pig
primat
viruslik
particl
nake
rna
layer
dnarna
plasmid
provid
protect
challeng
lethal
dose
infecti
agent
administ
tumor
cell
prophylact
therapeut
efficaci
achiev
cancer
immunotherapi
moreov
recombin
particl
replicon
rna
encapsul
liposom
improv
deliveri
target
replicon
rna
vector
also
subject
clinic
trial
overal
immun
selfrepl
rna
virus
provid
high
transient
express
level
antigen
result
gener
neutral
antibodi
respons
protect
lethal
challeng
safe
condit
vaccin
variou
anim
model
elicit
humor
cellular
immun
respons
gener
neutral
antibodi
well
protect
challeng
pathogen
tumor
cell
final
summari
clinic
trial
alreadi
conduct
progress
appli
selfrepl
rna
virus
present
howev
due
larg
number
public
avail
possibl
present
key
find
exampl
vaccin
develop
selfrepl
viral
vector
express
system
engin
rna
virus
describ
ssrna
virus
share
featur
high
level
rna
replic
cytoplasm
provid
basi
extrem
transient
express
heterolog
gene
howev
differ
polar
ssrna
genom
selfrepl
rna
virus
requir
design
vector
specif
featur
moreov
viral
vector
util
differ
form
indic
individu
type
virus
alphavirusbas
express
system
develop
differ
format
sfv
sin
vee
illustr
sfv
figur
case
basic
compon
repres
alphaviru
nonstructur
gene
respons
rapid
high
quantiti
cytoplasm
rna
replic
replicationdefici
system
carri
gene
interest
goi
downstream
gene
alphaviru
express
vector
driven
subgenom
promot
rna
replicon
vector
gener
vitro
transcript
direct
rna
immun
case
product
recombin
particl
vitro
transcrib
rna
alphaviru
helper
vector
cotransfect
coelectropor
babi
hamster
kidney
bhk
cell
replicationprofici
system
util
fulllength
vector
goi
introduc
either
downstream
gene
structur
gene
vitro
transcrib
rna
appli
immun
due
presenc
fulllength
alphaviru
genom
rna
replicationprofici
particl
gener
dna
layer
system
appli
plasmid
carri
altern
nonstructur
gene
fulllength
genom
goi
direct
immun
dna
vector
system
approach
describ
proven
effici
immun
studi
present
among
flavivirus
kunjin
viru
west
nile
viru
yellow
fever
viru
dengu
viru
tickborn
enceph
viru
engin
develop
vector
dna
rna
recombin
particl
deliveri
kunjin
viru
vector
goi
insert
first
codon
core
protein
last
codon
envelop
gene
frame
rest
viral
polyprotein
figur
goi
express
initi
fusion
kunjin
viru
polyprotein
process
individu
protein
introduct
flank
proteas
sequenc
allow
cleavag
kunjin
viru
sequenc
express
recombin
protein
facilit
vector
product
system
engin
transfect
kunjin
viru
replicon
rna
tetkuncprmec
packag
cell
line
express
system
engin
wherebi
replic
mv
rescu
clone
dna
express
construct
figur
revers
genet
allow
rescu
recombin
measl
viru
helper
cell
line
foreign
gene
introduc
phosphoprotein
p
matrix
protein
hemagglutinin
h
larg
protein
l
respect
measl
viru
genom
transfect
helper
cell
line
recombin
mv
construct
plasmid
express
mv
polymeras
l
gene
follow
transfer
syncytia
vero
vaccin
cell
cultur
day
recombin
mv
particl
harvest
reach
cytopath
effect
vaccin
recombin
mv
construct
plasmid
express
mv
polymeras
l
gene
follow
transfer
syncytia
vero
cell
cultur
day
recombin
mv
particl
harvest
reach
cytopath
effect
b
c
vaccin
develop
infecti
diseas
classic
base
live
attenu
inactiv
infecti
agent
recent
approach
vaccin
recombinantli
express
antigen
immunogen
viral
nonvir
deliveri
system
introduc
repertoir
context
immun
surfac
protein
antigen
elicit
strong
humor
cellular
immun
respons
vaccin
anim
show
protect
challeng
lethal
dose
infecti
agent
tumor
cell
type
nonvir
vector
appli
includ
liposom
immunostimulatori
complex
iscom
compos
adjuv
quil
peptid
multipl
antigen
peptid
map
also
known
dendrim
number
viral
vector
base
adenovirus
alphavirus
avipoxivirus
enterovirus
flavivirus
measl
virus
mv
rhabdovirus
vaccinia
virus
engin
vaccin
develop
context
selfrepl
rna
viru
vector
proven
highli
effici
immun
studi
variou
anim
model
among
rna
virus
rabi
viru
rabv
vesicular
stomat
viru
vsv
belong
rhabdoviru
famili
carri
singlestrand
rna
ssrna
genom
neg
polar
likewis
mv
possess
negativesens
ssrna
genom
contrast
flavivirus
alphavirus
posit
polar
west
nile
viru
kunjin
viru
common
flavivirus
appli
immun
studi
similarli
express
vector
engin
alphavirus
semliki
forest
viru
sfv
sindbi
viru
sin
venezuelan
equin
enceph
viru
vee
review
variou
selfrepl
rna
viru
vector
describ
applic
recombin
viru
particl
rna
replicon
layer
dna
plasmid
compar
moreov
exampl
given
util
selfrepl
rna
viru
system
immun
studi
rabv
vsv
subject
express
vector
engin
figur
similar
mv
revers
genet
appli
effici
recoveri
vsv
base
recombin
vaccinia
viru
vsv
n
p
l
gene
insert
downstream
promot
intern
ribosom
entri
site
ire
role
vaccinia
viru
provid
rna
polymeras
howev
vaccinia
viru
caus
strong
cytopath
effect
transfect
cell
vaccinia
viru
dna
polymeras
contribut
homolog
recombin
fulllength
genom
helper
plasmid
vaccinia
viru
may
also
contamin
recombin
viru
stock
reason
bhk
cell
line
stabli
express
rna
polymeras
engin
vaccinia
virusfre
system
rabv
addit
rhabdoviru
vector
chimer
viruslik
particl
vlp
gener
express
vsv
glycoprotein
vsvg
tran
sfv
replicon
introduct
mutat
sfv
promot
packag
infecti
sfv
pseudoparticl
system
provid
high
biosafeti
standard
vsvg
share
homolog
sfv
genom
rabv
vsv
subject
express
vector
engin
figur
similar
mv
revers
genet
appli
effici
recoveri
vsv
base
recombin
vaccinia
viru
vsv
n
p
l
gene
insert
downstream
promot
intern
ribosom
entri
site
ire
role
vaccinia
viru
provid
rna
polymeras
howev
vaccinia
viru
caus
strong
cytopath
effect
transfect
cell
vaccinia
viru
dna
polymeras
contribut
homolog
recombin
fulllength
genom
helper
plasmid
vaccinia
viru
may
also
contamin
recombin
viru
stock
reason
bhk
cell
line
stabli
express
rna
polymeras
engin
vaccinia
virusfre
system
rabv
addit
rhabdoviru
vector
chimer
viruslik
particl
vlp
gener
express
vsv
glycoprotein
vsvg
tran
sfv
replicon
introduct
mutat
sfv
promot
packag
infecti
sfv
pseudoparticl
system
provid
high
biosafeti
standard
vsvg
share
homolog
sfv
genom
structur
gene
hepfluri
strain
except
g
protein
cv
strain
foreign
gene
insert
n
p
g
l
gene
respect
cmv
cytomegaloviru
promot
g
rabi
g
protein
l
rabi
l
protein
rabi
matrix
protein
n
rabi
nucleocapsid
protein
selfrepl
rna
viru
vector
frequent
use
vaccin
develop
infecti
diseas
variou
type
cancer
vector
base
ssrna
virus
posit
kunjin
viru
sfv
sin
vee
neg
mv
rabv
vsv
polar
util
express
viral
surfac
protein
tumor
antigen
follow
immun
studi
anim
model
moreov
vaccin
differ
approach
includ
recombin
particl
rna
replicon
layer
dna
plasmid
appli
target
vaccin
develop
infecti
diseas
compris
mainli
surfac
antigen
pathogen
virus
tabl
infecti
agent
tabl
obviou
target
vaccin
develop
antigen
influenza
viru
hiv
context
recombin
sfv
particl
express
influenza
nucleoprotein
np
demonstr
strong
immun
respons
similarli
veebas
express
hemagglutinin
ha
elicit
strong
immun
respons
even
provid
protect
challeng
viru
chicken
likewis
express
swine
influenza
viru
ha
gene
vee
vector
protect
swine
influenza
viru
challeng
anoth
studi
swine
influenza
ha
gene
express
replicationdefici
alphaviru
particl
show
spread
vaccin
revers
virul
intend
host
pig
nonhost
mous
speci
specif
humor
respons
observ
pig
also
protect
influenza
viru
challeng
recombin
mv
vector
carri
ha
gene
also
appli
vaccin
studi
also
vsv
vector
util
vaccin
develop
influenza
viru
instead
use
fulllength
ha
express
stalk
domain
ha
gener
chimer
ha
cha
antigen
intramuscular
intranas
immun
mice
result
ha
stalkspecif
crossreact
antibodi
primeboost
vaccin
provid
protect
lethal
challeng
homolog
heterolog
influenza
strain
significantli
superior
intranas
administr
structur
gene
hepfluri
strain
except
g
protein
cv
strain
foreign
gene
insert
n
p
g
l
gene
respect
cmv
cytomegaloviru
promot
g
rabi
g
protein
l
rabi
l
protein
rabi
matrix
protein
n
rabi
nucleocapsid
protein
selfrepl
rna
viru
vector
frequent
use
vaccin
develop
infecti
diseas
variou
type
cancer
vector
base
ssrna
virus
posit
kunjin
viru
sfv
sin
vee
neg
mv
rabv
vsv
polar
util
express
viral
surfac
protein
tumor
antigen
follow
immun
studi
anim
model
moreov
vaccin
differ
approach
includ
recombin
particl
rna
replicon
layer
dna
plasmid
appli
target
vaccin
develop
infecti
diseas
compris
mainli
surfac
antigen
pathogen
virus
tabl
infecti
agent
tabl
obviou
target
vaccin
develop
antigen
influenza
viru
hiv
context
recombin
sfv
particl
express
influenza
nucleoprotein
np
demonstr
strong
immun
respons
similarli
veebas
express
hemagglutinin
ha
elicit
strong
immun
respons
even
provid
protect
challeng
viru
chicken
likewis
express
swine
influenza
viru
ha
gene
vee
vector
protect
swine
influenza
viru
challeng
anoth
studi
swine
influenza
ha
gene
express
replicationdefici
alphaviru
particl
show
spread
vaccin
revers
virul
intend
host
pig
nonhost
mous
speci
specif
humor
respons
observ
pig
also
protect
influenza
viru
challeng
recombin
mv
vector
carri
ha
gene
also
appli
vaccin
studi
also
vsv
vector
util
vaccin
develop
influenza
viru
instead
use
fulllength
ha
express
stalk
domain
ha
gener
chimer
ha
cha
antigen
intramuscular
intranas
immun
mice
result
ha
stalkspecif
crossreact
antibodi
primeboost
vaccin
provid
protect
lethal
challeng
homolog
heterolog
influenza
strain
significantli
superior
intranas
administr
obviou
reason
hiv
popular
target
vaccin
develop
instanc
administr
kunjin
replicon
express
gag
antigen
balbc
mice
elicit
gagspecif
antibodi
protect
gagspecif
cell
respons
interestingli
singl
immun
kunjin
viru
particl
induc
higher
tcell
respons
protect
again
hiv
challeng
obtain
two
inject
furthermor
rna
optim
kunjin
viru
construct
siv
gagpol
demonstr
improv
effector
memori
central
memori
respons
well
protect
primat
alphaviru
vector
also
employ
hiv
vaccin
develop
immun
sfv
particl
express
env
gene
elicit
humor
cytotox
tlymphocyt
ctl
respons
mice
interestingli
prime
low
dose
dnabas
sfv
replicon
express
hiv
env
gagpolnef
fusion
prior
heterolog
boost
poxviru
mva
andor
hiv
protein
formul
glycopyranosyl
lipid
result
significantli
enhanc
immun
respons
moreov
macaqu
immun
vsv
vector
carri
siv
env
gene
neutral
antibodi
obtain
howev
challeng
anim
infect
contrast
vaccin
combin
gag
env
result
immun
rabv
vector
also
employ
express
siv
env
gag
macaqu
although
immun
respons
detect
rabv
glycoprotein
g
cellular
respons
obtain
siv
antigen
howev
replac
rabv
g
vsv
g
result
sivspecif
immun
respons
immun
macaqu
protect
siv
challeng
number
immun
studi
target
lethal
virus
ebola
lassa
virus
instanc
dosedepend
protect
ebola
viru
achiev
guinea
pig
immun
kunjin
viru
particl
express
ebola
viru
wildtyp
glycoprotein
gp
mutant
gp
similarli
african
green
monkey
subcutan
immun
kunjin
particl
carri
ebola
gp
mutant
protect
three
four
primat
obtain
challeng
zair
ebola
viru
applic
vsv
vector
express
ebola
gp
gene
also
provid
protect
macaqu
challeng
west
african
ebovmakuna
strain
likewis
protect
three
differ
ebola
strain
achiev
express
ebola
gp
vsv
vector
alphaviru
vector
also
util
vaccin
develop
ebola
viru
context
rna
replicon
deriv
attenu
vee
strain
appli
express
ebola
gp
nucleoprotein
np
immun
studi
show
veegp
alon
combin
veenp
provid
protect
balbc
mice
guinea
pig
contrast
veenp
alon
confer
protect
guinea
pig
mice
anoth
studi
mice
immun
vee
particl
express
ebola
np
protect
anim
ebola
viru
challeng
vsv
vector
subject
immun
studi
express
lassa
viru
glycoprotein
strain
josiah
sierra
leon
gener
protect
guinea
pig
singl
prophylact
inject
also
shown
macaqu
protect
challeng
genet
distinct
liberian
lassa
viru
isol
importantli
previou
vsvbase
lassa
viru
vaccin
impact
immun
vsvebola
gp
particl
furthermor
alphavirus
use
vaccin
develop
lassa
viru
guinea
pig
immun
vee
particl
express
lassa
viru
glycoprotein
nucleoprotein
show
protect
lethal
challeng
lassa
viru
furthermor
dual
express
approach
ebola
lassa
viru
glycoprotein
engin
led
protect
ebola
lassa
viru
challeng
number
viral
antigen
subject
vaccin
develop
current
relev
target
compris
dengu
viru
sever
acut
respiratori
syndrom
coronaviru
sarscov
middl
east
respiratori
syndrom
corona
viru
merscov
instanc
mice
immun
vee
particl
express
sarscov
glycoprotein
provid
protect
lethal
sarscov
challeng
furthermor
mice
immun
mv
vector
express
merscov
glycoprotein
result
induct
tcell
antibodi
respons
protect
lethal
dose
merscov
respiratori
syncyti
viru
rsv
also
target
recombin
mv
vector
express
rsv
fusion
protein
rsvf
immun
cotton
rat
induc
neutral
antibodi
rsv
protect
rsv
infect
lung
anoth
applic
lipid
nanoparticl
lnp
formul
engin
vee
rna
replicon
demonstr
protect
rsv
challeng
vaccin
mice
furthermor
immun
african
green
monkey
vee
particl
express
human
rsvf
metapneumoviru
f
hmpvf
protein
gener
rsvf
mpvfspecif
antibodi
result
protect
rsv
mpv
challeng
context
dengu
viru
vaccin
hybrid
mv
vector
express
hepat
b
surfac
antigen
hbsag
dengu
viru
envelop
protein
elicit
neutral
antibodi
mv
hbsag
anoth
studi
vaccin
mice
gener
antibodi
respons
protect
four
dv
serotyp
alphaviru
vector
also
evalu
dengu
vaccin
develop
express
two
configur
dengu
viru
e
antigen
prme
provid
protect
macaqu
moreov
singl
immun
balbc
mice
suffici
induc
neutral
antibodi
tcell
respons
neonat
immun
durabl
could
boost
later
life
provid
protect
challeng
dengu
viru
addit
viral
target
evalu
vaccin
develop
list
tabl
vaccin
develop
also
extend
infecti
diseas
caus
viral
infect
tabl
context
mice
vaccin
sfv
vector
express
plasmodium
falciparum
antigen
elicit
immunolog
memori
similarli
strong
immun
longterm
protect
mycobacterium
tuberculosi
obtain
mice
immun
sin
plasmid
dna
vector
carri
tuberculosi
antigen
furthermor
express
botulinum
neurotoxin
layer
sfv
dna
plasmid
elicit
antibodi
lymphoprolif
respons
immun
balbc
mice
coexpress
granulocytemacrophag
colonystimul
factor
gmcsf
enhanc
immun
respons
replicationdefici
sfv
particl
carri
brucella
abortu
translat
initi
factor
subject
immun
studi
balbc
mice
result
protect
challeng
virul
b
abortu
strain
anoth
studi
sin
vector
util
express
protect
antigen
pa
bacillu
antraci
swiss
webster
mice
lead
gener
specif
neutral
antibodi
partial
protect
challeng
pathogen
bacteria
recombin
sin
vector
appli
express
class
major
histocompat
complexrestrict
epitop
plasmodium
yoelii
circumsporozoit
protein
cs
induc
strong
epitopespecif
tcell
respons
high
degre
protect
malaria
infect
mice
anoth
approach
develop
malaria
vaccin
involv
applic
live
attenu
mv
vaccin
express
recombin
antigen
malaria
modifi
replicationcompet
due
gener
neutral
antibodi
vsv
immun
booster
possibl
vsvgpova
ctl
respons
similar
potenc
obtain
stateoftheart
adenoviru
administr
observ
complet
protect
challeng
listeria
monocytogen
obtain
mice
context
prion
diseas
sfv
dna
rna
recombin
particl
employ
express
prion
protein
prnp
allow
gener
monoclon
antibodi
prnp
immun
mice
although
directli
appli
vaccin
develop
gener
monoclon
antibodi
use
basic
research
diagnost
prion
alphaviru
vector
also
appli
develop
vaccin
staphylococcu
enterotoxin
b
seb
subcutan
administr
vee
particl
express
seb
result
protect
challeng
wildtyp
seb
mice
number
immun
studi
carri
selfrepl
rna
viru
vector
area
oncolog
tabl
instanc
attenu
oncolyt
mv
strain
edmonstonb
mvedm
strain
demonstr
antitumor
activ
mvedm
strain
caus
signific
cytopath
effect
normal
tissu
select
infect
replic
tumor
cell
base
evalu
cell
line
primari
cancer
cell
xenograft
syngen
model
bcell
nonhodgkin
lymphoma
ovarian
cancer
glioblastoma
multiform
breast
prostat
cancer
context
tumor
regress
obtain
scid
mice
human
lymphoma
xenograft
intratumor
inject
mvedm
moreov
coadministr
mv
vector
express
carcinoembryon
antigen
cea
thyroid
sodium
iodid
symport
ni
mice
ovarian
xenograft
show
superior
tumor
regress
comparison
treatment
either
mvcea
mvni
alon
improv
deliveri
enhanc
efficaci
signal
lymphocyt
activ
molecul
slam
ablat
mutat
hemagglutinin
protein
combin
display
singlechain
antibodi
epiderm
growth
factor
receptor
egfr
incorpor
mv
vector
tumor
target
tumor
regress
significantli
extend
surviv
observ
intratumor
administr
mv
evalu
mvcea
deliveri
mammari
tumor
model
reveal
signific
delay
tumor
growth
prolong
surviv
moreov
intratumor
administr
mvcea
vector
show
tumor
growth
delay
improv
surviv
subcutan
xenograft
model
rhabdovirus
also
appli
cancer
therapi
vsv
vector
lack
preexist
immun
human
demonstr
high
suscept
cancer
cell
particularli
vsv
vector
subject
aggress
pancreat
ductal
adenocarcinoma
pdac
show
superior
sendai
viru
rsv
clinic
relev
human
pancreat
cell
line
although
respons
vari
one
cell
line
anoth
moreov
evalu
ten
pdac
cell
line
three
vsv
vector
express
wildtyp
matrix
protein
show
activ
vsvmediat
apoptosi
howev
high
constitut
express
ifnstimul
gene
isg
discov
three
cell
line
also
contribut
resist
apoptosi
kunjin
viru
replicon
express
granulocyt
colonystimul
factor
gmcsf
subject
intratumor
administr
result
cure
less
mice
establish
colon
carcinoma
melanoma
subcutan
inject
led
regress
lung
metastasi
moreov
kunjin
vector
engin
express
ctl
epitop
protein
induc
tcell
respons
provid
protect
challeng
epitheli
tumor
mice
studi
kunjin
vlp
effect
rna
replicon
dna
vector
alphaviru
vector
appli
mani
studi
cancer
vaccin
principl
tumorassoci
antigen
taa
immunomodul
cytokin
combin
therapi
taa
cytokin
taa
antibodi
cytokin
antibodi
even
microrna
mirna
evalu
context
intratumor
inject
sfv
particl
express
enhanc
green
fluoresc
protein
egfp
show
apoptosi
induct
mice
implant
human
nonsmal
cell
lung
carcinoma
cell
mice
furthermor
intratumor
administr
sfv
particl
balbc
mice
implant
sarcoma
kbalb
sarcoma
colon
tumor
result
signific
tumor
growth
inhibit
also
vaccin
mice
sfv
rna
replicon
express
show
protect
challeng
colon
tumor
cell
singl
intratumor
inject
sfvlacz
rna
result
day
surviv
extens
mice
exist
tumor
similarli
sinlacz
vector
demonstr
therapeut
efficaci
mous
colon
carcinoma
model
despit
target
specif
cell
sin
vector
show
suscept
mediastin
lymph
node
mln
induc
effector
memori
tcell
display
robust
cytotox
wellcharacter
human
carcinoembryon
antigen
cea
elicit
neutral
antibodi
vee
vlp
immun
moreov
melanoma
antigen
tyrosinerel
protein
melanoma
antigen
tyrosinas
tyr
express
vee
vector
instanc
immun
mice
particl
result
growth
inhibit
transplant
melanoma
strong
therapeut
potenc
vaccin
vlp
effici
combin
veetyr
particl
furthermor
vee
particl
carri
tyr
gene
induc
immun
respons
tumor
protect
mice
administr
vee
vlp
alon
initi
vaccin
plasmid
dna
follow
boost
vee
vlp
breast
cancer
target
sever
therapeut
prophylact
vaccin
studi
sin
plasmid
dna
carri
neu
gene
subject
immun
mice
result
inhibit
growth
challeng
tumor
cell
interestingli
vaccin
two
day
tumor
challeng
ineffici
contrast
immun
primeboost
protocol
sinneu
dna
follow
adenoviru
vector
carri
neu
gene
prolong
surviv
mice
due
potenc
stimul
antigenspecif
tcell
dendrit
cell
dc
transduc
veeneu
particl
result
highlevel
transgen
express
dc
matur
secret
proinflammatori
cytokin
robust
neuspecif
tcell
antineu
igg
respons
observ
singl
immun
moreov
regress
larg
establish
tumor
obtain
anoth
taa
attract
immunotherapi
sixtransmembran
epitheli
antigen
prostat
steap
demonstr
upregul
multipl
cancer
cell
line
transgen
adenocarcinoma
mous
prostat
tumorbear
mice
preimmun
vee
vlp
express
steap
demonstr
strong
immun
respons
significantli
prolong
overal
surviv
therapeut
affect
assess
mice
tumor
result
modest
signific
delay
tumor
growth
furthermor
vee
vlp
appli
express
prostat
stem
cell
antigen
psca
tramp
mice
initi
immun
psca
dna
plasmid
follow
veepsca
vlp
deliveri
outcom
specif
immun
respons
protect
tumor
challeng
tramp
mice
also
prostatespecif
membran
antigen
psma
express
vee
vector
demonstr
strong
humor
cellular
immun
respons
subcutan
immun
mice
vee
vlp
express
prostatespecif
antigen
psa
use
immun
mice
follow
challeng
tramp
cell
vee
vlp
capabl
infect
dc
vitro
induc
robust
psaspecif
respons
vivo
tumor
vaccin
anim
show
low
psa
express
level
tumor
growth
significantli
delay
antigen
express
mastocytoma
tumor
trigger
immun
studi
gene
code
antigen
sfv
particl
express
gene
elicit
strong
ctl
respons
protect
immun
mice
challeng
tumor
interest
taa
vaccin
target
protein
human
papilloma
viru
hpv
immun
sfv
particl
express
hpv
type
show
strong
hpvspecif
ctl
activ
erad
hpvtransform
tumor
similarli
immun
mice
vee
particl
carri
gene
prevent
tumor
develop
elimin
establish
tumor
vaccin
anim
anoth
studi
tattoo
inject
sfvhpv
particl
result
antigen
express
skin
drain
lymph
node
lead
tenfold
lower
antigen
level
comparison
intramuscular
administr
howev
tattoo
inject
provid
higher
equal
level
immun
respons
cytokin
play
import
role
immunotherapi
vaccin
develop
instanc
express
sfv
sin
vector
context
sfv
vector
express
induc
tumor
regress
longterm
tumorfre
surviv
colon
carcinoma
model
repeat
intratumor
administr
increas
antitumor
respons
anoth
studi
immun
sfvluciferas
particl
evalu
woodchuck
model
hepatocellular
carcinoma
hcc
induc
infect
woodchuck
hepat
viru
whv
high
luciferas
express
level
observ
tumor
secret
measur
serum
intratumor
inject
tumorbear
woodchuck
partial
tumor
remiss
seen
tumor
volum
reduc
tumor
growth
restor
time
plasmid
vector
provid
liverspecif
induc
express
compar
particl
deliveri
lpkcmyc
transgen
mous
model
hcc
overexpress
cmyc
gene
liver
transgen
anim
induc
spontan
hepat
tumor
characterist
similar
human
hcc
intratumor
administr
result
tumor
growth
arrest
surviv
rate
mice
treat
plasmid
dna
show
slightli
lower
surviv
rate
despit
higher
level
serum
strong
antitumor
respons
mice
like
due
apoptosi
type
ifn
respons
induc
sfv
particl
recombin
sin
particl
demonstr
target
tumor
cell
scid
mice
encourag
intraperiton
inject
particl
mice
establish
ovarian
tumor
treatment
result
system
target
erad
tumor
cell
without
advers
effect
observ
gliomabear
mice
immun
particl
induc
apoptosi
glioma
cell
facilit
uptak
apoptot
cell
dc
provid
prolong
surviv
vaccin
anim
moreov
dc
isol
bone
marrow
transduc
sfv
vector
express
treatment
brain
tumorbear
mice
outcom
prolong
surviv
immun
anim
anoth
studi
particl
test
rat
glioma
low
dose
vlp
treatment
result
reduct
tumor
volum
wherea
highdos
vlp
show
reduct
tumor
volum
moreov
intratumor
administr
oncolyt
sfv
particl
express
egfp
gener
signific
tumor
regress
melanomabear
scid
mice
cytokin
also
evalu
alphavirusbas
express
ovarian
colon
cancer
model
enhanc
vector
provid
tenfold
higher
level
express
convent
sfv
vector
appli
immun
balbc
mice
vitro
verif
secret
activ
mice
subcutan
kbalb
tumor
inject
particl
led
tumor
regress
disappear
tumor
treat
anim
moreov
gmcsf
immunostimulatori
cytokin
express
sfv
vector
intraperiton
administr
sfvgmcsf
particl
evalu
ovarian
mous
tumor
model
result
activ
macrophag
tumor
cytotox
although
prolong
surviv
tumorbear
mice
achiev
tumor
growth
inhibit
two
week
among
growth
factor
target
vaccin
develop
vascular
endotheli
growth
factor
receptor
introduc
sfv
vector
immun
mice
particl
result
substanti
inhibit
tumor
growth
spread
pulmonari
metastas
furthermor
vaccin
led
tumor
inhibit
mice
establish
colon
tumor
metastat
mammari
tumor
anoth
approach
sfv
particl
carri
endostatin
gene
administ
mice
bear
brain
tumor
treatment
result
substanti
reduct
intratumor
vascular
tumor
section
signific
inhibit
tumor
growth
endostatin
serum
level
threefold
higher
day
intraven
administr
sfvendostatin
comparison
administr
retrovirusbas
gcsapendostatin
promot
inhibit
angiogenesi
establish
tumor
anoth
approach
sin
vector
employ
express
fusion
protein
protein
calreticulin
crt
er
bind
transport
particip
antigen
process
present
major
histocompat
complex
mhc
class
immun
mice
bear
tumor
particl
significantli
increas
tcell
precursor
strong
antitumor
respons
furthermor
signific
reduct
lung
tumor
nodul
observ
immunocompromis
balbc
mice
combin
therapi
evalu
alphavirusbas
gene
deliveri
instanc
sfv
layer
dna
vector
engin
express
one
four
domain
coimmun
sfv
replicon
dna
express
survivin
antigen
verifi
mice
result
effici
humor
cellular
immun
respons
survivin
moreov
tumor
growth
inhibit
surviv
rate
melanoma
mous
model
improv
furthermor
immun
sfv
hpv
combin
sunitib
singl
lowdos
irradi
enhanc
intratumor
ratio
antitumor
effector
cell
myeloidderiv
suppressor
cell
tripl
treatment
tumorbear
mice
demonstr
enhanc
antitumor
efficaci
provid
tumorfre
surviv
interest
approach
compris
introduct
micro
vector
toler
associ
sfv
gene
condit
replic
viru
abl
replic
neuron
allow
target
glioma
otherwis
sensit
evalu
mous
astrocytoma
cell
pretreat
human
glioblastoma
cell
show
increas
oncolyt
potenc
moreov
singl
intraperiton
inject
mice
implant
orthotop
glioma
show
signific
inhibit
tumor
growth
improv
surviv
rate
selfrepl
rna
viru
vector
subject
sever
clinic
studi
albeit
inferior
level
comparison
adenoviru
aav
lentiviru
vector
instanc
healthi
volunt
subject
lowdos
pfu
immun
vsvbase
ebola
vaccin
rvsvzebov
express
zair
ebola
viru
glycoprotein
doubleblind
studi
comparison
previou
studi
high
dose
pfu
seriou
advers
event
occur
overal
safeti
good
lowdos
immun
improv
earli
toler
gener
inferior
antibodi
respons
fail
prevent
vaccineinduc
arthriti
dermat
vascul
furthermor
vsv
particl
express
gag
gene
evalu
clinic
trial
safeti
immunogen
random
doubleblind
placebocontrol
doseescal
studi
healthi
hivneg
volunt
receiv
pfu
rvsv
gag
vaccin
intramuscularli
month
vaccin
individu
show
antibodi
respons
vsv
gagspecif
tcell
respons
detect
overal
safeti
profil
good
alphavirus
subject
gene
therapi
vaccin
studi
one
approach
replicationdefici
sfv
particl
encapsul
liposom
promot
passiv
target
tumor
initi
intraperiton
administr
encapsul
sfvlacz
particl
show
enhanc
accumul
scid
mice
implant
lncap
prostat
tumor
liposomeencapsul
sfv
particl
express
subunit
gener
activ
secret
cell
next
encapsul
particl
administ
intraven
termin
ill
melanoma
kidney
carcinoma
patient
phase
clinic
trial
patient
show
five
tenfold
increas
plasma
level
maximum
toler
dose
determin
infecti
particl
safeti
profil
good
phase
doseescal
trial
conduct
prostat
cancer
patient
vee
particl
express
psma
patient
castrationresist
metastat
prostat
cancer
crpc
receiv
five
dose
either
iu
iu
veepsma
particl
week
studi
show
toxic
good
toler
vaccin
howev
weak
psmaspecif
immun
respons
detect
clinic
benefit
obtain
anoth
clinic
trial
vee
particl
express
cea
tumor
antigen
demonstr
effici
infect
dc
vee
particl
could
repeatedli
administ
overcam
high
titer
neutral
antibodi
elev
regulatori
cell
treg
allow
induct
clinic
relev
ceaspecif
cell
antibodi
respons
anoth
approach
vee
particl
express
cytomegaloviru
cmv
gb
fusion
protein
evalu
phase
random
doubleblind
clinic
trial
intramuscular
subcutan
immun
week
cmv
seroneg
adult
volunt
show
good
studi
conduct
replicationdefici
recombin
particl
howev
promis
result
also
obtain
layer
dna
plasmid
vector
limit
number
studi
appli
administr
rna
replicon
result
quit
encourag
obviou
advantag
use
nucleic
acidbas
deliveri
elimin
risk
viru
progeni
product
recombin
event
hand
superior
deliveri
prolong
durat
express
achiev
recombin
viral
particl
especi
appli
replicationprofici
oncolyt
virus
reason
difficult
make
recommend
relat
deliveri
format
use
choic
target
play
import
role
decis
make
similarli
practic
imposs
favor
one
viral
vector
system
anoth
revers
genet
system
engin
mv
rhabdovirus
packag
cell
line
flavivirus
sure
facilit
recombin
particl
product
eas
use
although
packag
cell
line
also
gener
alphavirus
straightforward
vitro
rna
transcript
provid
mean
suffici
prepar
replicon
rna
particl
immun
studi
obvious
plasmid
dna
directli
appli
vaccin
comparison
viral
vector
also
nonvir
deliveri
system
selfrepl
rna
virus
sure
consid
competit
figur
tabl
extens
comparison
deliveri
system
within
scope
review
exampl
address
clearli
adenovirusbas
vaccin
develop
gene
therapi
longer
histori
gener
multitud
vector
improv
also
result
number
clinic
trial
similarli
herp
simplex
viru
hsv
vector
frequent
appli
hsvgmcsf
instanc
subject
phase
human
clinic
trial
glioblastoma
melanoma
patient
hsv
vector
recent
approv
fda
use
standard
patient
care
relat
nonvir
vector
recent
dendrimerrna
nanoparticl
demonstr
protect
immun
lethal
challeng
ebola
viru
influenza
viru
toxoplasma
gondii
singl
inject
balbc
mice
overal
selfrepl
rna
viral
vector
possess
sever
attract
featur
presenc
rna
replicon
provid
effici
mean
rapid
gener
larg
number
rna
copi
immedi
protein
translat
cytoplasm
host
cell
moreov
strong
subgenom
promot
util
alphavirus
gener
extrem
level
heterolog
gene
express
transient
natur
express
also
advantag
immun
studi
furthermor
risk
integr
viral
gene
host
genom
viral
rna
degrad
within
day
case
immun
layer
alphaviru
dna
vector
approxim
lower
dose
requir
compar
immun
convent
plasmid
dna
although
strong
immun
respons
obtain
protect
challeng
lethal
pathogen
tumor
cell
achiev
even
tumor
regress
observ
anim
establish
tumor
technolog
develop
necessari
much
develop
invest
vector
design
includ
mutant
vector
enhanc
signal
target
dc
fusion
construct
furthermor
quit
effort
paid
evalu
differ
target
antigen
immunogen
sever
studi
particularli
clinic
trial
indic
although
targetspecif
immun
respons
obtain
invest
requir
find
right
dose
achiev
optim
respons
one
area
recent
receiv
much
attent
combin
therapi
tumorassoci
antigen
taa
combin
cytokin
antibodi
well
drug
radiat
coadminist
cytokin
addit
optim
adjuv
composit
stabil
issu
case
rna
deliveri
need
address
research
area
certainli
provid
progress
make
immunotherapi
import
approach
prophylact
therapeut
applic
right
dose
achiev
optim
respons
one
area
recent
receiv
much
attent
combin
therapi
tumorassoci
antigen
taa
combin
cytokin
antibodi
well
drug
radiat
coadminist
cytokin
addit
optim
adjuv
composit
stabil
issu
case
rna
deliveri
need
address
research
area
certainli
provid
progress
make
immunotherapi
import
approach
prophylact
therapeut
applic
